MAM
ADVM

Marquette Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Marquette Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,012
Closed -$45.3K – 198
2023
Q4 		$45.3K Hold
6,012
– – 0.01% 141
2023
Q3 		$90.2K Sell
6,012
-6,127
-50% -$110K 0.02% 109
2023
Q2 		$193K Hold
12,139
– – 0.05% 81
2023
Q1 		$87.1K Hold
12,139
– – 0.02% 122
2022
Q4 		$70.3K Buy
12,139
+2,448
+25% +$18.6K 0.02% 137
2022
Q3 		$92K Sell
9,691
-3,586
-27% -$47.1K 0.03% 112
2022
Q2 		$159K Buy
13,277
+6,702
+102% +$70.2K 0.05% 91
2022
Q1 		$86K Buy
6,575
+1,175
+22% +$17.2K 0.02% 159
2021
Q4 		$95K Buy
5,400
+840
+18% +$16.8K 0.02% 154
2021
Q3 		$99K Buy
+4,560
New +$116K 0.02% 141
2017
Q4 		– Sell
-2,600
Closed -$95K – 64
2017
Q3 		$95K Hold
2,600
– – 0.04% 81
2017
Q2 		$65K Buy
2,600
+225
+9% +$6.15K 0.03% 84
2017
Q1 		$64K Buy
+2,375
New +$67.6K 0.03% 87

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Marquette Asset Management's ADVM Position: Q1 2024 in Review

Marquette Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2024, closing a stake of 6,012 shares — an estimated $45.3K sold.

Marquette Asset Management first reported a position in ADVM in Q1 2017 and held it in 13 quarters. The position peaked at $193K in Q2 2023. 61 funds tracked by Wall St. Rank hold ADVM as of Q1 2024.

  • Marquette Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • Marquette Asset Management sold 6,012 Adverum Biotechnologies shares in Q1 2024, an estimated $45.3K.
  • Marquette Asset Management first reported a position in Adverum Biotechnologies in Q1 2017 and held it in 13 quarters.
  • Marquette Asset Management's Adverum Biotechnologies position peaked at $193K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2024.

Based on Marquette Asset Management's 13F filing for Q1 2024, filed 6 May 2024.